A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure.

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2015

At a glance

  • Drugs Alagebrium chloride (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms BENEFICIAL
  • Sponsors Synvista Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2010 Trial design and rationale published in the European Journal of Heart Failure.
    • 15 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00516646)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top